Table 1.

Published/presented combination studies with idelalisib, ibrutinib, and venetoclax in CLL

Agents	Reference	No. of patients	Response rate	PFS	OS
Idelalisib + rituximab	9, 10	220	77% ORR	12-mo PFS = 66%	Not reached
Idelalisib + bendamustine, bendamustine/rituximab, fludarabine, chlorambucil, or chlorambucil/rituximab	62	IB = 18	82% ORR; 10% CR	24-mo PFS = 57%	Not reported
		IBR = 15
		IF = 12
		ICh = 15
		IChR = 14
Ibrutinib + rituximab	63	40 (36 previously treated)	95% ORR; 8% CR	18-mo PFS = 78%	18-mo OS = 84%
Ibrutinib + ofatumumab	64	71	83% ORR	12-mo PFS 85%-90% depending on schedule	Not reported
Ibrutinib + lenalidomide	65	11	100% ORR	91% at 263 d	100% at 263 d
Venetoclax + rituximab	20	49 (34 evaluable for response)	88% ORR; 32% CR/CRi	Not reported	Not reported

CR, complete response; CRi, complete response with incomplete marrow recovery; IB, idelalisib + bendamustine; IBR, idelalisib + bendamustine + rituximan; ICh, idelalisib + chlorambucil; IChR, idelalisib + chlorambucil + rituximab; IF, idelalisib + fludarabine; OR, overall response; ORR, overall response rate.